Serum Institute partners with RDIF to make 300 mn doses of Sputnik V

RDIF says SII can make combination doses of Astra-Sputnik in future

Sputnik V’s production in India has received a shot in the arm as the developers of the Russian Covid-19 vaccine and Serum Institute of India (SII) announced a partnership agreement on Tuesday to manufacture more than 300 million doses, with production set to start in September. With this deal, the total manufacturing capacity for Sputnik V in India crosses 1.1 billion doses annually.

As Kirill Dmitriev, chief executive officer (CEO), Russian Direct Investment Fund (RDIF), the Russian sovereign wealth fund, pointed out, SII will be in a position to produce the mix-and-match dose combination of the AstraZeneca-Oxford vaccine and Sputnik